Evidence map›Paper›PMID 29051415›Full record

ArticleToxics2016

Development of a Biomarker for Penconazole: A Human Oral Dosing Study and a Survey of UK Residents' Exposure.

Craig Sams, Kate Jones, Karen S Galea, Laura MacCalman, John Cocker, Paul Teedon, John W Cherrie, Martie van Tongeren

Abstract read
In one paragraph

Article in Toxics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The MAK collection for occupational health and safety · 2026
    Article
  2. Article
  3. Highly sensitive colorimetric assay for penconazole using gold nanostar-graphene quantum dot composite.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Craig SamsHealth and Safety Laboratory (HSL), Buxton SK17 9JZ, UK. craig.sams@hsl.gsi.gov.uk.
Kate JonesHealth and Safety Laboratory (HSL), Buxton SK17 9JZ, UK. kate.jones@hsl.gsi.gov.uk.ORCID 0000-0001-8923-2999
Karen S GaleaCentre for Human Exposure Science, Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK. karen.Galea@iom-world.org.
Laura MacCalmanCentre for Human Exposure Science, Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK. Laura.MacCalman@iom-world.org.
John CockerHealth and Safety Laboratory (HSL), Buxton SK17 9JZ, UK. john.cocker@hsl.gsi.gov.uk.
Paul TeedonSchool of Engineering and the Built Environment, Glasgow Caledonian University, Glasgow G4 0BA, UK. Paul.Teedon@gcu.ac.uk.
John W CherrieCentre for Human Exposure Science, Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK. john.cherrie@iom-world.org.
Martie van TongerenCentre for Human Exposure Science, Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK. Martie.VanTongeren@iom-world.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Penconazole is a widely used fungicide in the UK; however, to date, there have been no peer-reviewed publications reporting human metabolism, excretion or biological monitoring data. The objectives of this study were to i) develop a robust analytical method, ii) determine biomarker levels in volunteers exposed to penconazole, and, finally, to iii) measure the metabolites in samples collected as part of a large investigation of rural residents' exposure. An LC-MS/MS method was developed for penconazole and two oxidative metabolites. Three volunteers received a single oral dose of 0.03 mg/kg body weight and timed urine samples were collected and analysed. The volunteer study demonstrated that both penconazole-OH and penconazole-COOH are excreted in humans following an oral dose and are viable biomarkers. Excretion is rapid with a half-life of less than four hours. Mean recovery of the administered dose was 47% (range 33%-54%) in urine treated with glucuronidase to hydrolyse any conjugates. The results from the residents' study showed that levels of penconazole-COOH in this population were low with >80% below the limit of detection. Future sampling strategies that include both end of exposure and next day urine samples, as well as contextual data about the route and time of exposure, are recommended.

Indexed as

biological monitoringbiomarkersexposurefungicidepenconazoleresidentssprayurine

Identifiers

PMID29051415
PMCPMC5606630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.